Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
K. Milinis & C. A. Young. (2016) Systematic review of the influence of spasticity on quality of life in adults with chronic neurological conditions. Disability and Rehabilitation 38:15, pages 1431-1441.
Read now
Read now
Carlo Pozzilli. (2013) Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Review of Neurotherapeutics 13:sup2, pages 49-54.
Read now
Read now
Ralf Gold. (2013) Multiple sclerosis spasticity epidemiology – key publications. Expert Review of Neurotherapeutics 13:sup2, pages 45-46.
Read now
Read now
Articles from other publishers (9)
Julie Schjødtz Hansen, Rikke Middelhede Hansen, Thor Petersen, Stefan Gustavsen, Annette Bang Oturai, Finn Sellebjerg, Eva Aggerholm Sædder, Helge Kasch, Peter Vestergaard Rasmussen, Nanna Brix Finnerup & Kristina Bacher Svendsen. (2021) The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial. Brain Sciences 11:9, pages 1212.
Crossref
Crossref
Lorenzo G. Mantovani, Paolo Cozzolino, Paolo A. Cortesi & Francesco Patti. (2020) Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation 40:4, pages 319-326.
Crossref
Crossref
Stergios Tsiormpatzis. (2019) Effects of shiatsu on the health-related quality of life of a person with secondary progressive multiple sclerosis: A mixed methods N-of-1 trial within a whole systems research case study. European Journal of Integrative Medicine 32, pages 101006.
Crossref
Crossref
M. Sorosina, F. Clarelli, L. Ferrè, A. M. Osiceanu, N. T. Unal, E. Mascia, V. Martinelli, G. Comi, F. Benigni, F. Esposito & F. Martinelli Boneschi. (2018) Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. European Journal of Neurology 25:7, pages 934-e70.
Crossref
Crossref
K. Milinis, A. Tennant & C.A. Young. (2016) Spasticity in multiple sclerosis: Associations with impairments and overall quality of life. Multiple Sclerosis and Related Disorders 5, pages 34-39.
Crossref
Crossref
VL Stevenson, A Gras, JI Bárdos & J Broughton. (2015) The high cost of spasticity in multiple sclerosis to individuals and society. Multiple Sclerosis Journal 21:12, pages 1583-1592.
Crossref
Crossref
Tatjana Knezevic, Ljubica Konstantinovic, Sindi Rodic, Calogero Foti, Jelena Drulovic, Jelena Dackovic, Dejan Nikolic, Ivana Petronic & Dobrivoje S. Stokic. (2015) Validity and reliability of the Serbian version of Patient-Reported Impact of Spasticity Measure in multiple sclerosis. International Journal of Rehabilitation Research 38:3, pages 199-205.
Crossref
Crossref
Jose Eustasio Meca‐Lallana, Rocío Hernández‐Clares & Ester Carreón‐Guarnizo. (2015) Spasticity in multiple sclerosis and role of glatiramer acetate treatment. Brain and Behavior 5:9.
Crossref
Crossref
F Kamin, P S Rommer, M Abu-Mugheisib, W Koehler, F Hoffmann, A Winkelmann, R Benecke & U K Zettl. (2014) Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity. Spinal Cord 53:2, pages 109-113.
Crossref
Crossref